Molecular diagnosis of multistage hepatocarcinogenesis

Michiie Sakamoto, Kathryn Effendi, Yohei Masugi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Human hepatocellular carcinoma is recognized as a good model for multistage carcinogenesis, as the malignant steps from chronic liver disease through to advanced human hepatocellular carcinoma are relatively clear. We address the activation of different molecular pathways during hepatocarcinogenesis that is especially useful in the diagnosis of pathological multistage human hepatocellular carcinoma. In chronic liver disease, the gene-expression signature as well as the degree of liver fibrosis could help us to predict the development of human hepatocellular carcinoma or survival outcome after treatment for human hepatocellular carcinoma. Several genes, such as HSP70, CAP2 and GPC3, have been identified as potential biomarkers for early human hepatocellular carcinoma. Classical oncogenes or tumor suppressor genes, such as beta-catenin and p53, are mutated during the progression from early to advanced human hepatocellular carcinoma. Also, the presence of hepatoblastic feature like CK19 in advanced human hepatocellular carcinoma can be used as a predictor of aggressive human hepatocellular carcinoma. Although many advances have been made in the diagnosis of multistage hepatocarcinogenesis, we still need further useful markers to more precisely evaluate each step of hepatocarcinogenesis for better treatment choices, and that will promote future molecular-targeted therapy.

Original languageEnglish
Article numberhyq099
Pages (from-to)891-896
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume40
Issue number9
DOIs
Publication statusPublished - 2010 Jul 4

Fingerprint

Hepatocellular Carcinoma
Liver Diseases
Chronic Disease
Molecular Targeted Therapy
beta Catenin
Human Development
Tumor Suppressor Genes
Oncogenes
Transcriptome
Liver Cirrhosis
Carcinogenesis
Biomarkers
Survival
Genes

Keywords

  • Advanced HCC
  • Chronic hepatitis
  • Early HCC
  • Hepatocarcinogenesis
  • Molecular markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Molecular diagnosis of multistage hepatocarcinogenesis. / Sakamoto, Michiie; Effendi, Kathryn; Masugi, Yohei.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. 9, hyq099, 04.07.2010, p. 891-896.

Research output: Contribution to journalArticle

@article{7e0f2456f8e04fa8bd7e145f4f23912e,
title = "Molecular diagnosis of multistage hepatocarcinogenesis",
abstract = "Human hepatocellular carcinoma is recognized as a good model for multistage carcinogenesis, as the malignant steps from chronic liver disease through to advanced human hepatocellular carcinoma are relatively clear. We address the activation of different molecular pathways during hepatocarcinogenesis that is especially useful in the diagnosis of pathological multistage human hepatocellular carcinoma. In chronic liver disease, the gene-expression signature as well as the degree of liver fibrosis could help us to predict the development of human hepatocellular carcinoma or survival outcome after treatment for human hepatocellular carcinoma. Several genes, such as HSP70, CAP2 and GPC3, have been identified as potential biomarkers for early human hepatocellular carcinoma. Classical oncogenes or tumor suppressor genes, such as beta-catenin and p53, are mutated during the progression from early to advanced human hepatocellular carcinoma. Also, the presence of hepatoblastic feature like CK19 in advanced human hepatocellular carcinoma can be used as a predictor of aggressive human hepatocellular carcinoma. Although many advances have been made in the diagnosis of multistage hepatocarcinogenesis, we still need further useful markers to more precisely evaluate each step of hepatocarcinogenesis for better treatment choices, and that will promote future molecular-targeted therapy.",
keywords = "Advanced HCC, Chronic hepatitis, Early HCC, Hepatocarcinogenesis, Molecular markers",
author = "Michiie Sakamoto and Kathryn Effendi and Yohei Masugi",
year = "2010",
month = "7",
day = "4",
doi = "10.1093/jjco/hyq099",
language = "English",
volume = "40",
pages = "891--896",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Molecular diagnosis of multistage hepatocarcinogenesis

AU - Sakamoto, Michiie

AU - Effendi, Kathryn

AU - Masugi, Yohei

PY - 2010/7/4

Y1 - 2010/7/4

N2 - Human hepatocellular carcinoma is recognized as a good model for multistage carcinogenesis, as the malignant steps from chronic liver disease through to advanced human hepatocellular carcinoma are relatively clear. We address the activation of different molecular pathways during hepatocarcinogenesis that is especially useful in the diagnosis of pathological multistage human hepatocellular carcinoma. In chronic liver disease, the gene-expression signature as well as the degree of liver fibrosis could help us to predict the development of human hepatocellular carcinoma or survival outcome after treatment for human hepatocellular carcinoma. Several genes, such as HSP70, CAP2 and GPC3, have been identified as potential biomarkers for early human hepatocellular carcinoma. Classical oncogenes or tumor suppressor genes, such as beta-catenin and p53, are mutated during the progression from early to advanced human hepatocellular carcinoma. Also, the presence of hepatoblastic feature like CK19 in advanced human hepatocellular carcinoma can be used as a predictor of aggressive human hepatocellular carcinoma. Although many advances have been made in the diagnosis of multistage hepatocarcinogenesis, we still need further useful markers to more precisely evaluate each step of hepatocarcinogenesis for better treatment choices, and that will promote future molecular-targeted therapy.

AB - Human hepatocellular carcinoma is recognized as a good model for multistage carcinogenesis, as the malignant steps from chronic liver disease through to advanced human hepatocellular carcinoma are relatively clear. We address the activation of different molecular pathways during hepatocarcinogenesis that is especially useful in the diagnosis of pathological multistage human hepatocellular carcinoma. In chronic liver disease, the gene-expression signature as well as the degree of liver fibrosis could help us to predict the development of human hepatocellular carcinoma or survival outcome after treatment for human hepatocellular carcinoma. Several genes, such as HSP70, CAP2 and GPC3, have been identified as potential biomarkers for early human hepatocellular carcinoma. Classical oncogenes or tumor suppressor genes, such as beta-catenin and p53, are mutated during the progression from early to advanced human hepatocellular carcinoma. Also, the presence of hepatoblastic feature like CK19 in advanced human hepatocellular carcinoma can be used as a predictor of aggressive human hepatocellular carcinoma. Although many advances have been made in the diagnosis of multistage hepatocarcinogenesis, we still need further useful markers to more precisely evaluate each step of hepatocarcinogenesis for better treatment choices, and that will promote future molecular-targeted therapy.

KW - Advanced HCC

KW - Chronic hepatitis

KW - Early HCC

KW - Hepatocarcinogenesis

KW - Molecular markers

UR - http://www.scopus.com/inward/record.url?scp=77956110536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956110536&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq099

DO - 10.1093/jjco/hyq099

M3 - Article

VL - 40

SP - 891

EP - 896

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

M1 - hyq099

ER -